Jinain Pharmaceutics Reports Q3 Sales Below 300 Million KRW... KRX Adds Reasons for Listing Review
[Asia Economy Reporter Ji Yeon-jin] Jinain Pharmaceutical announced on the 14th that its sales revenue for the third quarter of this year was recorded at less than 300 million KRW.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
In response, the Korea Exchange announced on the same day that an additional reason for the delisting suitability review was added, as the quarterly report submitted by Jinain Pharmaceutical confirmed that the sales revenue for the last quarter was less than 300 million KRW.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
